Sayyid

Catawba Research Appoints Syed Faridi as New Head of Business Development

Retrieved on: 
Thursday, February 29, 2024

Catawba Research , a prominent global clinical research organization (CRO), welcomes Syed Faridi as its Vice President of Global Business Development.

Key Points: 
  • Catawba Research , a prominent global clinical research organization (CRO), welcomes Syed Faridi as its Vice President of Global Business Development.
  • Syed, an industry veteran with nearly two decades of experience in clinical research, brings an unparalleled level of expertise as a sales leader.
  • Having made significant contributions at Clinical Ink, Medidata Solutions, and Parexel, Syed's arrival is a game-changer for Catawba Research, elevating its ability to drive business and accelerate revenue growth.
  • The consistent recruitment of top-tier leaders like Syed ensures that we not only maintain, but elevate our trajectory of unparalleled growth," said Andy Silverman , CEO at Catawba Research.

PodcastOne (PODC) Signs Exclusive Multi-Year Partnership with Rabia Chaudry’s Nighty Night Anthology Podcast Series

Retrieved on: 
Monday, October 16, 2023

LOS ANGELES, CA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - PodcastOne (NASDAQ: PODC), a leading podcast platform and a subsidiary of LiveOne (NASDAQ: LVO), announced that it has obtained the exclusive distribution and sales rights to the podcast Nighty Night hosted by New York Times best-selling author and attorney Rabia Chaudry (Adnan’s Story).

Key Points: 
  • The creepy tales will be a mix of both original content and lesser known classics delivered with a modern spin.
  • Since its launch in late 2021, Nighty Night has released forty-one nightmare inducing episodes.
  • “We have been long-time fans of Rabia, for her work as an esteemed podcast host and for her work as a revered advocate.
  • Rabia and her work with Adnan Sayed told through the podcast Serial, put podcasting on the map for mainstream audiences.

Modernization--Chinese style

Retrieved on: 
Friday, October 21, 2022

The world's most populous country now stands ready to embrace a modernization model with its own characteristics.

Key Points: 
  • The world's most populous country now stands ready to embrace a modernization model with its own characteristics.
  • The model contains elements common to the modernization processes of all countries, but it is more characterized with features unique to the Chinese context, Xi said.
  • Its success in eradicating absolute poverty over the past years is a major step toward attaining a key goal of Chinese modernization: common prosperity.
  • The CPC National Congress and the Central Committee it elects are the highest leading bodies of the Party.

March of Dimes Launches Livestream Brand - Powered on Dimes™ - and Adds Cryptocurrency & Non Fungible Tokens as Ways to Support Mom, Baby Health

Retrieved on: 
Thursday, August 11, 2022

ARLINGTON, Va., Aug. 11, 2022 /PRNewswire/ -- In an effort to raise greater awareness and drive action in the maternal and infant health crisis, March of Dimes is now making it easier for digital communities to support its mission by facilitating peer-to-peer fundraising through Powered On Dimes™ and by accepting digital currency. Tragically, the U.S. remains among the most dangerous developed nations for childbirth, especially for women and babies of color. To change the course of this crisis, March of Dimes is stepping up its efforts to cultivate digital audiences ahead of its third annual Giving Day on August 25, with a goal of raising $500,000.

Key Points: 
  • Tragically, the U.S. remains among the most dangerous developed nations for childbirth, especially for women and babies of color.
  • Through Powered by Dimes, any content creators seeking to make a positive impact can sign up to create a charity stream to elevate awareness among younger audiences and raise money to support families.
  • Through platforms likes Twitch, YouTube and Facebook Gaming, content creators who raise 5,000 dimes can fund over six hours of prematurity research, for example.
  • We support research, lead programs and provide education and advocacy so that every baby can have the best possible start.

Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker

Retrieved on: 
Wednesday, June 1, 2022

WOODCLIFF LAKE, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that AOP Orphan Pharmaceuticals GmbH, a member of the AOP Health Group (“AOP Health”), with whom Eagle entered into a licensing agreement in August 2021, submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for landiolol, a short-acting, intravenous (“IV”), cardio-selective beta-1 adrenergic blocker. The submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia (“SVT”), including atrial fibrillation and atrial flutter.

Key Points: 
  • The submission seeks approval for landiolol for the short-term reduction of ventricular rate in patients with supraventricular tachycardia (SVT), including atrial fibrillation and atrial flutter.
  • We believe that landiolol has the potential to become a cornerstone therapy in the management of tachycardia in critically ill patients.
  • Landiolol is an ultra-short-acting, cardio-selective, beta-1 adrenoceptor blocker, which reduces heart rate and has a minimal effect over cardiac contractility (inotropy).
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.

Kaspien Appoints David Sayyed as New Vice President of Brand Growth

Retrieved on: 
Tuesday, October 26, 2021

SPOKANE, Wash., Oct. 26, 2021 /PRNewswire/ -- Kaspien Holdings Inc. (NASDAQ: KSPN) ("Kaspien" or the "Company"), a leading e-commerce marketplace growth platform, today announced the appointment of David "Dave" Sayyed as its new Vice President of Brand Growth.

Key Points: 
  • SPOKANE, Wash., Oct. 26, 2021 /PRNewswire/ -- Kaspien Holdings Inc. (NASDAQ: KSPN) ("Kaspien" or the "Company"), a leading e-commerce marketplace growth platform, today announced the appointment of David "Dave" Sayyed as its new Vice President of Brand Growth.
  • In this newly created role, Sayyed will leverage his expertise in strategic brand growth and developing frameworks to strengthen Kaspien's brand portfolio of existing partner relationships as well as enhance the current services and offerings for customers.
  • Sayyed brings over 15 years of experience in brand and account management in e-commerce, including serving in enterprise-level account management roles at Amazon, Coca-Cola, and Nestl Purina.
  • The VP of Brand Growth position will have direct reporting responsibilities to Chief Operating Officer Mitchell Bailey and work closely with the executive team on other strategic initiatives.

Eagle Pharmaceuticals Announces Licensing Agreement with AOP Orphan for U.S. Commercial Rights to Landiolol, a Beta-1 Adrenergic Blocker

Retrieved on: 
Monday, August 9, 2021

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (AOP Orphan), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States.

Key Points: 
  • Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (Eagle or the Company) today announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH (AOP Orphan), a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States.
  • Landiolol is a short-acting, ultra-high selective beta-1 adrenoceptor blocker developed by AOP Orphan that has a selective effect on heart rate over cardiac contractility.
  • Under the terms of the agreement, Eagle will facilitate the U.S. regulatory pathway for the approval of Landiolol.
  • AOP Orphan Pharmaceuticals GmbH is an international pharmaceutical company with its registered office in Vienna and a focus on rare and special diseases.

Andersen Global Enters Sudan as Africa Expansion Remains High Priority

Retrieved on: 
Thursday, August 27, 2020

Andersen Global has entered into a Collaboration Agreement with the law firm Ali Gailoub and Samia El Hashmi in Sudan.

Key Points: 
  • Andersen Global has entered into a Collaboration Agreement with the law firm Ali Gailoub and Samia El Hashmi in Sudan.
  • The addition of the Khartoum-based firm establishes Andersen Globals presence in the country and continues the organizations expansion on the continent.
  • Ali Gailoub and Samia El Hashmi is another high-quality practice that bolsters our platform in Africa which now includes more than 36 countries, Andersen Global Chairman and Andersen CEO Mark Vorsatz said.
  • Andersen Global is an international association of legally separate, independent member firms comprised of tax and legal professionals around the world.